Literature DB >> 23337060

Nasopharyngeal carcinoma: a retrospective review of demographics, treatment and patient outcome in a single centre.

R J Colaco1, G Betts, A Donne, R Swindell, B K Yap, A J Sykes, N J Slevin, J J Homer, L W Lee.   

Abstract

AIMS: Nasopharyngeal cancer (NPC) is relatively uncommon, especially in the Western world. We report our single institution experience of 20 years of data in 128 patients with NPC, including responses to different treatment modalities and outcomes by histological subtype.
MATERIALS AND METHODS: NPC patients presenting from 1992 to 2005 were located on the cancer registry database. Demographic data included age, gender, length of presenting symptoms and stage. World Health Organization classification (2005) was used for histological subtyping. The date of recurrence and survival outcomes were analysed using Kaplan-Meier curves.
RESULTS: Presentation data were analysed from 128 patients; the survival analysis included 123 patients. The median age at presentation was 57.7 years. Stage III and IV presentation rates were 34 and 38%, respectively. The most common presenting symptom was a palpable neck lump (55%) and the median duration of symptoms was 16 weeks. Forty-eight patients received radiotherapy alone and 75 received chemoradiotherapy. The median overall survival in chemoradiotherapy patients was 80.3 months versus 28.5 months with radiotherapy alone (P = 0.003). A significant difference was also seen with recurrence-free survival (RFS) (P = 0.017). Type 1 keratinising carcinoma had a significantly worse overall survival (P = 0.04) and a similar but non-statistically significant trend was seen for RFS (P = 0.051). The multivariate analysis for overall survival showed that histological subtype (hazard ratio 2.7, 95% confidence interval 1.3-5.5, P = 0.034), age (hazard ratio 2.3, 95% confidence interval 1.1-4.9, P = 0.018) and N stage (hazard ratio 3.7, 95% confidence interval 1.4-9.4, P = 0.024) were prognostic factors.
CONCLUSIONS: We present the first large-scale, single-centre retrospective review of NPC in a UK-based population. Demographic data were similar to that in other Western populations, with a significantly worse survival outcome in the keratinising group. Further prospective study of outcome in Western populations accounting for newer radiotherapy techniques such as intensity-modulated radiotherapy and dose escalation, particularly in the keratinising population who were more likely to present with an isolated local recurrence, is recommended.
Copyright © 2012 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23337060     DOI: 10.1016/j.clon.2012.10.006

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  32 in total

1.  Non-endemic locoregionally advanced nasopharyngeal carcinoma: long-term outcome after induction plus concurrent chemoradiotherapy in everyday clinical practice.

Authors:  Paolo Boscolo-Rizzo; Giancarlo Tirelli; Monica Mantovani; Vittorio Baggio; Valentina Lupato; Giacomo Spinato; Alessandro Gava; Maria Cristina Da Mosto
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-11-04       Impact factor: 2.503

2.  Diagnostic performance of FDG PET/CT to detect subclinical HNSCC recurrence 6 months after the end of treatment.

Authors:  Philippe Robin; Ronan Abgral; Gérald Valette; Pierre-Yves Le Roux; Nathalie Keromnes; Jean Rousset; Gaël Potard; Xavier Palard; Rémi Marianowski; Pierre-Yves Salaun
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-08-29       Impact factor: 9.236

3.  MicroRNA-130a-3p suppresses cell viability, proliferation and invasion in nasopharyngeal carcinoma by inhibiting CXCL12.

Authors:  Rongfeng Qu; Yan Sun; Yarong Li; Chunmei Hu; Guang Shi; Yan Tang; Dongrui Guo
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

4.  Long noncoding RNA LINC00460 aggravates invasion and metastasis by targeting miR-30a-3p/Rap1A in nasopharyngeal carcinoma.

Authors:  Xiaodong Hu; Weiwei Liu; Xue Jiang; Bin Wang; Liping Li; Jian Wang; Jinhua Ma
Journal:  Hum Cell       Date:  2019-08-14       Impact factor: 4.174

5.  LncRNA NEAT1/let-7a-5p axis regulates the cisplatin resistance in nasopharyngeal carcinoma by targeting Rsf-1 and modulating the Ras-MAPK pathway.

Authors:  Fei Liu; Yong Tai; Jiqing Ma
Journal:  Cancer Biol Ther       Date:  2018-04-09       Impact factor: 4.742

6.  Inhibition of store-operated Ca2+ entry counteracts the apoptosis of nasopharyngeal carcinoma cells induced by sodium butyrate.

Authors:  Wei Huang; Caiping Ren; Guoling Huang; Jie Liu; Weidong Liu; Lei Wang; Bin Zhu; Xiangling Feng; Jia Shi; Jinlong Li; Xiaomeng Xia; Wei Jia; Jiawen Chen; Yuxiang Chen; Xingjun Jiang
Journal:  Oncol Lett       Date:  2016-12-07       Impact factor: 2.967

7.  Camptothecin inhibits the progression of NPC by regulating TGF-β-induced activation of the PI3K/AKT signaling pathway.

Authors:  Ben-Shan Li; Ji-Yi Huang; Jing Guan; Long-Hua Chen
Journal:  Oncol Lett       Date:  2018-05-10       Impact factor: 2.967

8.  The effect of histological subtypes on survival outcome in nasopharyngeal carcinoma after extensive follow up.

Authors:  San-Gang Wu; Chen-Lu Lian; Jun Wang; Wen-Wen Zhang; Jia-Yuan Sun; Qin Lin; Zhen-Yu He
Journal:  Ann Transl Med       Date:  2019-12

9.  The prognostic significance of race in nasopharyngeal carcinoma by histological subtype.

Authors:  Katelyn O Stepan; Angela L Mazul; S Andrew Skillington; Randal C Paniello; Jason T Rich; Jose P Zevallos; Ryan S Jackson; Patrik Pipkorn; Sean Massa; Sidharth V Puram
Journal:  Head Neck       Date:  2021-02-23       Impact factor: 3.821

10.  Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.

Authors:  Yuanyuan Zhao; Jing Zhang; Ying Tian; Cong Xue; Zhihuang Hu; Li Zhang
Journal:  Drug Des Devel Ther       Date:  2015-08-26       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.